| Staging in bipolar disorder: from theoretical framework to clinical utility M Berk, R Post, A Ratheesh, E Gliddon, A Singh, E Vieta, AF Carvalho, ... World Psychiatry 16 (3), 236-244, 2017 | 216 | 2017 |
| A systematic review and meta‐analysis of prospective transition from major depression to bipolar disorder A Ratheesh, C Davey, S Hetrick, M Alvarez‐Jimenez, C Voutier, ... Acta Psychiatrica Scandinavica 135 (4), 273-284, 2017 | 147 | 2017 |
| The predictive validity of bipolar at‐risk (prodromal) criteria in help‐seeking adolescents and young adults: a prospective study A Bechdolf, A Ratheesh, SM Cotton, B Nelson, AM Chanen, J Betts, ... Bipolar disorders 16 (5), 493-504, 2014 | 147 | 2014 |
| Broad clinical high‐risk mental state (CHARMS): Methodology of a cohort study validating criteria for pluripotent risk JA Hartmann, B Nelson, R Spooner, G Paul Amminger, A Chanen, ... Early Intervention in Psychiatry 13 (3), 379-386, 2019 | 115 | 2019 |
| Early intervention—an implementation challenge for 21st century mental health care PD McGorry, A Ratheesh, B O'Donoghue JAMA psychiatry 75 (6), 545-546, 2018 | 115 | 2018 |
| The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): a randomised, double-blind, placebo-controlled, multicentre clinical trial CG Davey, AM Chanen, SE Hetrick, SM Cotton, A Ratheesh, ... The Lancet Psychiatry 6 (9), 735-744, 2019 | 100 | 2019 |
| An International Society of Bipolar Disorders task force report: Precursors and prodromes of bipolar disorder GL Faedda, RJ Baldessarini, C Marangoni, A Bechdolf, M Berk, ... Bipolar disorders 21 (8), 720-740, 2019 | 93 | 2019 |
| Rationale and first results of developing at-risk (prodromal) criteria for bipolar disorder A Bechdolf, A Ratheesh, S J Wood, T Tecic, P Conus, B Nelson, ... Current pharmaceutical design 18 (4), 358-375, 2012 | 87 | 2012 |
| At-risk studies and clinical antecedents of psychosis, bipolar disorder and depression: a scoping review in the context of clinical staging JA Hartmann, B Nelson, A Ratheesh, D Treen, PD McGorry Psychological medicine 49 (2), 177-189, 2019 | 86 | 2019 |
| Psychosocial intervention with or without antipsychotic medication for first-episode psychosis: a randomized noninferiority clinical trial SM Francey, B O’Donoghue, B Nelson, J Graham, L Baldwin, HP Yuen, ... Schizophrenia Bulletin Open 1 (1), sgaa015, 2020 | 81 | 2020 |
| Clinical and demographic predictors of continuing remission or relapse following discontinuation of antipsychotic medication after a first episode of psychosis. A systematic review M Bowtell, A Ratheesh, P McGorry, E Killackey, B O'Donoghue Schizophrenia Research 197, 9-18, 2018 | 79 | 2018 |
| A novel multimodal digital service (moderated online social therapy+) for help-seeking young people experiencing mental ill-health: pilot evaluation within a national youth e … M Alvarez-Jimenez, S Rice, S D'Alfonso, S Leicester, S Bendall, I Pryor, ... Journal of medical Internet research 22 (8), e17155, 2020 | 78 | 2020 |
| Quetiapine v. lithium in the maintenance phase following a first episode of mania: randomised controlled trial M Berk, R Daglas, O Dandash, M Yücel, L Henry, K Hallam, C Macneil, ... The British Journal of Psychiatry 210 (6), 413-421, 2017 | 78 | 2017 |
| Neurocognitive functioning in the prodrome of mania—an exploratory study A Ratheesh, A Lin, B Nelson, SJ Wood, W Brewer, J Betts, M Berk, ... Journal of affective disorders 147 (1-3), 441-445, 2013 | 70 | 2013 |
| Rates and predictors of relapse following discontinuation of antipsychotic medication after a first episode of psychosis M Bowtell, S Eaton, K Thien, M Bardell-Williams, L Downey, A Ratheesh, ... Schizophrenia research 195, 231-236, 2018 | 68 | 2018 |
| Pluripotential risk and clinical staging: theoretical considerations and preliminary data from a transdiagnostic risk identification approach JA Hartmann, PD McGorry, L Destree, GP Amminger, AM Chanen, ... Frontiers in Psychiatry 11, 553578, 2021 | 62 | 2021 |
| Cannabidiol for treatment-resistant anxiety disorders in young people: an open-label trial M Berger, E Li, S Rice, CG Davey, A Ratheesh, S Adams, H Jackson, ... The Journal of clinical psychiatry 83 (5), 42111, 2022 | 60 | 2022 |
| A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don’t work well enough? S Dodd, M Bauer, AF Carvalho, H Eyre, M Fava, S Kasper, SH Kennedy, ... The World Journal of Biological Psychiatry 22 (7), 483-494, 2021 | 60 | 2021 |
| Bipolar at-risk criteria: an examination of which clinical features have optimal utility for identifying youth at risk of early transition from depression to bipolar disorders J Scott, S Marwaha, A Ratheesh, I Macmillan, AR Yung, R Morriss, ... Schizophrenia bulletin 43 (4), 737-744, 2017 | 58 | 2017 |
| Youth Depression Alleviation with Anti-inflammatory Agents (YoDA-A): a randomised clinical trial of rosuvastatin and aspirin M Berk, M Mohebbi, OM Dean, SM Cotton, AM Chanen, S Dodd, ... BMC medicine 18, 1-12, 2020 | 49 | 2020 |
